Schering Aktiengesellschaft

Piramal Imaging Sa

Institut Fur Diagnostikforschung Gmbh an Der Freien Universitat Berlin

Institut for Diagnostikforschung Gmbh an Der Freien Universitat

Institut Fue Diagnostikforschung Gmbh

Bayer Schering Pharma Ag

Vereniging Vu-windesheim

A. N. Nesmeyanov Institute of Organoelement Compounds, the Russian Academy of Science (ineos Ras)

Institute of the Human Brain, Russian Academy of Science (ihb Ras)

Ludger Dinkelborg

Christoph-Stephan Hilger

Dieter Heldmann

Friedhelm Blume

Wolfgang Kramp

Ulrich Speck

Keith Graham

Matthias Friebe

Hans-Martin Schier

Stephan Hilger

Johannes Platzek

Heribert Schmitt-Willich

Ulrich Niedballa

Wolfhard Semmler

Jurgen Conrad

Mathias Berndt

Lutz Lehmann

Klaus Urich

Peter Henklein

Norman Koglin

Yuri Belokon

Jens Schneider-Mergener

Christoph Stephan Hilger

Hans Martin Schier

Renate Steinbrecher

Reinhard Malin

Gabriele Kuttner

Sebastian Erber

Cornelius Frommel

Bernhard Noll

Wolfgang Hohne

Dietmar Berndorff

Heidemarie Goerner

Stephan Duda

Gunnar Tepe

Heribert Miklautz

Matthias Berndt

Fedorovna Olga Kuznetsova

Nikolaevna Raisa Krasikowa

Olga Fedorovna Kuznetsova

Raisa Nikolaevna Krasikowa

Bernhard Marcel Tijink

Stephanie Sieger

Dieter Schering Aktiengesellschaft Moosmayer

Giovanni Philogen Srl Neri

The compounds and the synthesis of [F-18]-labeled L-glutamic acid, [F-18]-labeled L-glutamate, their derivatives as set forth in formula (I) and their uses are described.

[F-18]-labeled L-glutamic acid, [F-18]-labeled L-glutamine, derivatives thereof and use thereof and processes for their preparation

What is described are the compounds and the synthesis of [F-18]-labelled L-glutamic acid, [F-18]-labelled L-glutamate, their derivatives of the formula (I) and their use.

[F-18]-labelled L-glutamic acid and L-glutamine derivatives (I), their use and processes for their preparation

A radiolabeled implantable device includes a base, a first layer including Cu and a radioactive isotope on the base, and a second layer including Sn on the first layer. Preferably, the base is formed of stainless steel and the radioactive isotope is a radioisotope of Re, such asRe orRe. Alternately, radioisotopes of the following elements may be used: Be, Sc, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Ga, Ge, As, Y, Zr, Nb, Mo, Tc, Ru, Rh, Pd, Ag, Cd, In, Sn, Sb, Te, Hf, Ta, W, Os, Ir, Pt, Au, Hg, Tl, Pb, Bi, Po, At, Th, Pa, U, Np, Pu, Am, Cm, Bk, Cf, Es, Fm, Md, No, Lr. In addition, a process for producing a radiolabeled implantable device includes depositing a first layer including Cu and a radioactive isotope on a base, and depositing a second layer including Sn on the first layer. The process may further include removing CrOfrom the base and/or rinsing the base prior to depositing the first layer thereon.

Radioactive implantable devices and methods and apparatuses for their production and use

The invention relates to radioactive stents, characterized in that the stent is coated on the surface with the radioactive isotope, as well as processes for their production.

Stents with a radioactive surface coating, processes for their production and their use for restenosis prophylaxis

New chelating agents as well as their tricarbonyl complexes with technetium and rhenium and the use of these compounds in radiodiagnosis and radiotherapy are described. The new chelating agents are coupled to substances that accumulate in the diseased tissue.

Chelating agents as well as their tricarbonyl complexes with technetium and rhenium

The invention relates to a process for therapeutic treatment of proliferative diseases, which is characterized in that first an administration catheter is placed on the site of the lesion, and a radioactive substance is administered topically via the catheter, then the catheter is again removed, and the radioactive substance remains on the site of the lesion.

Process for therapeutic treatment of proliferative diseases

The present invention concerns novel complexes for use in the diagnosis of vascular diseases, methods of manufacturing such complexes and diagnostic agents containing them. These complexes strongly enrich themselves in atherosclerotic plaques and are thus suitable for use in non-invasive procedures for diagnosing atherosclerosis.

Complex compounds for diagnosis of vascular diseases

These invention relates to metal-complexing, cysteine-free peptides which may be coupled to an organ-specific probe directly or via a linker and are thus enriched as conjugates specifically in tumors, organs, tissues or centers of inflammation. The organ-specific probes used are, for example, antibodies or part-sequences of antibodies against tumor-associated antigens, e.g. the carcino-embryonal antigen (CEA, which are thus specifically enriched in tumors. The invention also relates to processes for producing the metal-complexing cysteine-free peptides and their conjugates. The present invention also relates to the use of the conjugates as components of a kit for in vivo diagnosis or in vivo therapy and radio-pharmaceuticals containing these conjugates together with radio-isotopes. The organ-specific conjugates are used to image tumors, organs or centers of inflammation.

Metal-binding cystein-free peptides for diagnostic and therapeutical purposes, methods for their production, and pharmaceuticals containing these compounds

Type S.sub.3 N.sub.2 chelators for radioactive isotopes, their metal

Chealators of type XN.sub.1 S.sub.1 X.sup.1 for radioactive isotopes,

Growing community of inventors

Berlin, Germany

Ludger Dinkelborg